In a deal worth around USD435m Swiss ADC therapeutics grants Swedish Orphan Biovitrum (SOBI) the rights to market freshly approved Zynlonta outside the US.
Tag Archive for: Sobi
In a deal worth around USD435m Swiss ADC therapeutics grants Swedish Orphan Biovitrum (SOBI) the rights to market freshly approved Zynlonta outside the US.